| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ranolazine (formerly CVT-303, RS 43285-003; brand name Ranexa) is a approved anti-angina drug used to treat chronic angina. Ranolazine acts as a calcium uptake inhibitor via the sodium/calcium channel. As an anti-ischemic agent, it inhibits late sodium current that results in a reduction of Na+ dependent Ca2+ overload.
| ln Vitro |
|
|
|---|---|---|
| ln Vivo |
In rats undergoing left anterior descending coronary artery occlusion-reperfusion, ranolazine (bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) therapy dramatically lowers infarct size and cardiac troponin T release [3].
|
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rats (240-350 g)[3]
Doses: Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h) Route of Administration: Bolus injection; for 145 minutes Experimental Results: Dramatically decreased infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion. |
|
| References |
[1]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.
[2]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. [3]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. |
| Molecular Formula |
C24H33N3O4
|
|
|---|---|---|
| Molecular Weight |
427.54
|
|
| CAS # |
95635-55-5
|
|
| Related CAS # |
Ranolazine dihydrochloride;95635-56-6;Ranolazine-d3;1054624-77-9;Ranolazine-d5;1092804-87-9;Ranolazine-d8;1092804-88-0
|
|
| SMILES |
O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3390 mL | 11.6948 mL | 23.3896 mL | |
| 5 mM | 0.4678 mL | 2.3390 mL | 4.6779 mL | |
| 10 mM | 0.2339 mL | 1.1695 mL | 2.3390 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02360397 | Completed Has Results | Drug: ranolazine | Ventricular Premature Complexes Myocardial Ischemia |
Kent Hospital, Rhode Island | December 2014 | Phase 2 |
| NCT02252406 | Completed Has Results | Drug: Ranolazine Other: Placebo |
Stable Angina Metabolic Syndrome |
University of Florida | September 2015 | Phase 4 |
| NCT02239926 | Terminated Has Results | Drug: Ranolazine Drug: Placebo |
Diarrhea Predominant Irritable Bowel Syndrome |
Mayo Clinic | September 2014 | Phase 2 Phase 3 |
| NCT02133352 | Completed Has Results | Drug: Ranolazine | Pulmonary Hypertension Diastolic Left Ventricular Dysfunction |
Boston University | July 2011 | Phase 4 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
